凯发一触即发

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis

CMAJ. 2022-02; 
Kevin Yau, Christopher T Chan, Kento T Abe, Yidi Jiang, Mohammad Atiquzzaman, Sarah I Mullin, Ellen Shadowitz, Lisa Liu, Ema Kostadinovic, Tatjana Sukovic, Anny Gonzalez, Margaret E McGrath-Chong, Matthew J Oliver, Jeffrey Perl, Jerome A Leis, Shelly Bolotin, Vanessa Tran, Adeera Levin, Peter G Blake, Karen Colwill, Anne-Claude Gingras, Michelle A Hladunewich
Products/Services Used Details Operation
Mammalian Expression We used VHH72-hFc1X7 (VHH-72-Fc) as the synthetic standard for anti-spike and anti-RBD as described previously,10 whereas human anti-nucleocapsid IgG (clone HC2003, GenScript, no. A02039) was used for anti-nucleocapsid. Get A Quote

摘要

background: Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). methods: We conducted a prospective observational cohort study at 2 academic centres in Toronto, Canada, from Feb. 2, 2021, to July 20, 2021, which included 129 and 95 patients who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines, respectively. We measured SARS-CoV-2 immunoglobulin G antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD) and nucleocapsid protein (ant... More

关键词